Lilly’s oral GLP-1 drug delivers Ozempic-like efficacy in phase 3 diabetes trial
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo Nordisk’s injectable blockbuster, although the figures are down on Lilly’s midphase data.
GLP-1 Drugs May Protect Against Alzheimer’s
University of Florida A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects…
GLP-1 Weight-Loss Drugs May Guard Against Dementia
submitted by /u/Diamond-Is-Not-Crash [link] [comments]
Pfizer Pulls Plug On Weight Loss Pill Amid Liver Damage Fears
Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
Pfizer Halts Obesity Pill Tests Amid Safety Concerns – Newser
Pfizer Halts Obesity Pill Tests Amid Safety Concerns Newser Pfizer ends development of potential pill obesity treatment CNN NVO, LLY, GPCR & VKTX Stocks Gain Following PFE’s Obesity Study Setback Yahoo Finance Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk. Barron’s Pfizer scraps daily weight loss pill after liver injury in one patient CNBC
Companies seek a second obesity treatment revolution—in pill form
Smaller, more easily made drugs that target GLP-1 could treat obesity and diabetes with fewer side effects
HIMS All In Baby
Hi I have terrible written expression skills, but I am good at math. So bear with me through this post and youll be rewarded. Hims & Hers Market Cap: $6.5B Q1 2025 Guidance: HIMS is projecting to grow Revenues at 87% – 94% YoY. This is in the range of $520 million to $540 million. […]
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
New Pill Form of Semaglutide Shows Major Benefits for People With Diabetes
Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have recently gained attention for their effectiveness in managing weight gain, high blood sugar, and even reducing alcohol cravings. A new clinical […]
Muscle Wasting With GLP-1 Agonists
Are your patients wasting away? Dr Tamaan Osbourne-Roberts explains why lifestyle interventions are a key supplement to GLP-1 agonists for weight management. Medscape